-
FOXL2 (RPab)
FOXL2 (RPab)
- 中文名称：
- FOXL2 (RPab)
- 英文名称：
- FOXL2 (RPab)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59369
- 规格：
- 5 Slides|3 mL (RTU)|0.1 mL (Concentrate)|7 mL (RTU)|0.5 mL (Concentrate)
- 保存建议：
- Store at 2-8°C (Control Slides: Store at 20-25°C)
- 货期：
- 6-8周
- 来源宿主：
- Rabbit
- 反应种属：
- Human , Mouse , Pig , Bovine
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Polyclonal
同型:IgG
克隆号:N/A
特异性:N/A
纯度:N/A
形式：Anti-FOXL2 is a purified immunoglobullin fraction of rabbit antiserum that is a filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
浓度：N/A
- 说明书：
The Forkhead box L2 (FOXL2) gene encodes FOXL2, a transcription factor involved in ovarian development and function. Before birth and in adulthood, the FOXL2 protein regulates the growth and proliferation of hormone-producing ovarian granulosa cells. FOXL2 is also involved in the breakdown of fats, steroid hormones, and potentially harmful reactive oxygen species in the ovaries.
FOXL2 antibody is a relatively sensitive and highly specific marker for Sex Cord-Stromal Tumors (SCST). FOXL2 antibody expression is present in almost all SCSTs with a FOXL2 mutation or without a mutation. A specific somatic mutation in the FOXL2 gene has been found in Adult Granulosa Cell Tumor (402C-->G/C134W), which is present in 70-95% of Ovarian Adult Granulosa Cell Tumors but not in Ovarian Fibromas. This mutation is also present in 2 of 5 men with Adult Granulosa Cell Tumor but absent in Ovarian Juvenile Granulosa Cell Tumors. Studies have demonstrated that FOXL2 is expressed in Cervical Squamous Cancer. FOXL2 suppresses the proliferation and promotes apoptosis of Cervical Cancer cells mainly through decreasing Ki-67 expression and increasing Fas ligand expression. FOXL2 has also been found to restrain the invasiveness of Cervical Cancer cells; hence, FOXL2 might be a novel tumor suppressor in Cervical Cancer. A study has demonstrated that FOXL2 antibody is expressed in Breast Cancer and influences clinical outcome with improved recurrence-free survival in cases with nuclear expression. In a multivariate Cox model, nuclear FOXL2 was a significant prognostic factor in ER-positive patients treated with tamoxifen and tumors expressing nuclear FOXL2 were also more likely positive for stromal and/or cytoplasmic aromatase.
